Whether or not there is economic value of comprehensive genomic profiling likely depends on what tissue type and what tumor type we’re talking about, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Whether or not there is economic value of comprehensive genomic profiling likely depends on what tissue type and what tumor type we’re talking about, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Transcript
In addition to being able to match certain patients with cancer to targeted therapies and clinical trials, is there a cost-benefit argument that can be made for covering comprehensive genomic profiling?
Comprehensive genomic profiling has been available for a number of years now. Priority Health was one of the first health plans in the country to cover next-generation sequencing, but we covered it in very limited circumstances. In patients where there was limited tissue, especially in non-small cell lung cancer, it made more economic sense to do next-generation sequencing rather than individual tumor analyses. We covered it in patients who had poor prognosis cancers in which it was important to understand what optimal therapy was the first time around in patients who had unsuccessfully completed prior therapy and were interested in clinical trials.
So, we covered it in very limited circumstances because it was important to understand the molecular profile for making subsequent treatment decisions. I think the question of whether or not there is an economic value to testing is probably very dependent on what tissue type and what tumor type we’re talking about. We’ve published some information with Foundation Medicine about the utility of next-generation sequencing and how physicians are using that information. I think as time progresses and physicians become more experienced in using those test results, we’ll see greater utlitity.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More